arrow
L

Leonidas Apostolidis

dkfz and heidelberg university hospital
H指数:17
被引数:911

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinically actionable genomic and transcriptomic landscape of advanced neuroendocrine neoplasms

晚期神经内分泌肿瘤的临床可操作基因组学和转录组学景观

Med
IF11.8
2026-04-300
OAAI
Multi-layered molecular profiling informs the diagnosis and targeted therapy of desmoplastic small round cell tumor

多层分子分析为硬化性小圆细胞肿瘤的诊断和靶向治疗提供信息

2026-04-090
OA
Immunotherapy for Metastatic Pancreatic Neuroendocrine Tumors with High Mutational Burden and Mismatch Repair Alterations Following Treatment with Alkylating Chemotherapy

高突变负荷及错配修复异常的转移性胰腺神经内分泌肿瘤在烷化剂化疗后的免疫治疗

2025-11-030
PRE
DNA methylation patterns facilitate tracing the origin of neuroendocrine neoplasms

DNA甲基化模式有助于追踪神经内分泌肿瘤的起源

2025-10-270
OAAI
The sarcoma ring trial: a case-based analysis of inter-center agreement across 21 German-speaking sarcoma centers (vol 151, 30, 2024)

软组织肉瘤环状试验:一项基于病例的分析,评估德国21个讲德语的软组织肉瘤中心之间的中心间一致性(卷151,期30,2024)

2025-04-240
OA
Interim analysis of CABONEN: A multicenter phase II trial investigating cabozantinib in patients with advanced, low proliferative NEN G3

CABONEN研究的期中分析:一项多中心II期临床试验,旨在研究卡博赞替尼在晚期低增殖神经内分泌肿瘤G3患者中的疗效

2024-09-011
PRE
Ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors (RamuNET): An AIO phase II multicenter single-arm study

Ramucirumab联合达卡巴嗪治疗进行性高分化转移性胰腺神经内分泌肿瘤 (RamuNET): 一项AIO II期多中心单臂研究

2024-09-010
PRE
NCT/DKFZ MASTER handbook of interpreting whole-genome, transcriptome, and methylome data for precision oncology
2023-10-267
OAAI
Genomics-based personalized oncology of advanced thymic epithelial tumors
2023-04-040
PRE
Gene expression-based prediction of pazopanib efficacy in sarcoma
2022-09-014
PRE
Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy (Jun, 10.1038/s43018-022-00398-7, 2022)
2022-07-151
OAAI
Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy
2022-06-1713
OAAI